Discounted Cash Flow (DCF) Analysis Levered

G Medical Innovations Holdings Ltd (GMVD)

$3

+0.01 (+0.33%)
All numbers are in Millions, Currency in USD
Stock DCF: -643,114.45 | 3 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.144.347.894.905.0643.65376.633,249.9928,044.62242,001.10
Revenue (%)
Operating Cash Flow ----4.65-11.49-70.29-606.53-5,233.79-45,163.16-389,719.42
Operating Cash Flow (%)
Capital Expenditure -1.91-3.35-0.61-0.51-0.55-128.76-1,111.08-9,587.65-82,733.24-713,917.05
Capital Expenditure (%)
Free Cash Flow -1.91-3.35-0.61-5.15-12.04-199.05-1,717.60-14,821.45-127,896.41-1,103,636.47

Weighted Average Cost Of Capital

Share price $ 3
Beta -1.132
Diluted Shares Outstanding 3.07
Cost of Debt
Tax Rate 0.02
After-tax Cost of Debt 57.27%
Risk-Free Rate
Market Risk Premium
Cost of Equity -1.826
Total Debt 7.84
Total Equity 9.21
Total Capital 17.06
Debt Weighting 45.98
Equity Weighting 54.02
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.144.347.894.905.0643.65376.633,249.9928,044.62242,001.10
Operating Cash Flow ----4.65-11.49-70.29-606.53-5,233.79-45,163.16-389,719.42
Capital Expenditure -1.91-3.35-0.61-0.51-0.55-128.76-1,111.08-9,587.65-82,733.24-713,917.05
Free Cash Flow -1.91-3.35-0.61-5.15-12.04-199.05-1,717.60-14,821.45-127,896.41-1,103,636.47
WACC
PV LFCF -158.79-1,093.14-7,525.19-51,803.73-356,618.90
SUM PV LFCF -417,199.74

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 25.35
Free cash flow (t + 1) -1,125,709.20
Terminal Value -4,821,024.42
Present Value of Terminal Value -1,557,821.31

Intrinsic Value

Enterprise Value -1,975,021.05
Net Debt 1.81
Equity Value -1,975,022.86
Shares Outstanding 3.07
Equity Value Per Share -643,114.45